Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
No open-market purchase by an insider of Genprex was filed in the last 90 days. The latest on record was on Apr 21, 2023.
How often do Genprex insiders buy and sell shares?
Since 2018, Genprex insiders reported 8 open-market purchases and 2 sales on Forms 4 and 5, with purchases in 4 different years, most recently 2023.
Who is selling Genprex stock?
No open-market sale by an insider of Genprex (GNPX) was filed with the SEC in the last 90 days.
Do members of Congress trade GNPX?
Yes. Members of Congress disclosed 3 trades in Genprex (GNPX) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent is from Rep. Tim Moore (NC14).
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−97.9% (−$68.07) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $69.52 on Nov 20, 2025 to $1.45 on Nov 20, 2026 (−97.9%). Disclosed in this range: 2 insider trades, 0 pre-arranged insider sales, 2 Congress trades.
$-20$20$40$60$80$100$1.45
DecJan 2026FebMarAprMayJunJulAugSepOctNov
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.Show the 4 trades in this range as a list
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Austin, Tx.
Last 12 months
−97.9%
S&P 500 +5.7% over the same dates
Market value
$1.94M
Close of Nov 20, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 123K shares sold short (9.2% of shares outstanding), −1.3% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insider buying and selling since 2018
Insiders of Genprex reported 8 open-market purchases and 2 sales since 2018; purchases in 4 different years, most recently 2023.
Year
Bought
Sold
2026
—
$222×2 trades
2023
$42K2×2 trades
—
2021
$62K1×1 trade
—
2019
$1.6K1×1 trade
—
2018
$502K4×4 trades
—
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the public record for Genprex over the 12 months to Nov 21, 2026: 2 clinical trials.
Red flags in its filings
Aug 5
Notice of delisting or failure to meet listing rules
From the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Owners above 5%
No Schedule 13D or 13G filing on GNPX over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Late-stage clinical trials
0 active phase 3 trials and 2 active phase 2 trials led by this company, mostly in small cell lung cancer extensive stage, carcinoma, non-small cell lung. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Genprex filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 2 open-market sales (about $22, in 1 filing, by 1 person). One Form 4 can list many transactions. In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 0 open-market sales (about $0, in 0 filings). (Genprex on OQRO)
Congress. Members of Congress filed 3 disclosures on Genprex in the 12 months to Nov 19, 2026: 3 purchases and 0 sales, by 1 member. In the 12 months before that: 1 disclosure. The largest range: Rep. Tim Moore (NC14), $1,001 to $15,000, filed Jan 7, 2026.
Contracts, lobbying and filings. ClinicalTrials.gov shows 2 studys sponsored by the company updated in the period; the latest, "Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Os..." (Phase 2, status recruiting), was updated on Sep 16, 2026, with primary completion listed for 2028-03. FINRA short interest for GNPX on the settlement date of Oct 30, 2026 was 123,259 shares (-1.33% on the previous report), about 1 days of average volume.
Company reports, price and press. Genprex filed a Form 8-K on Aug 5, 2026 (Item 3.01) that OQRO classes as: received a notice from its stock exchange. The company's own opening sentence of that report reads: "On August 4, 2026, the Company was formally notified that the Panel determined that the Company has regained compliance with the Bid Price Requirement."
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Genprex filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 2 open-market sales (about $22, in 1 filing, by 1 person). One Form 4 can list many transactions.
In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 0 open-market sales (about $0, in 0 filings).
The largest sale: Brent M Longnecker, Director, about $12, filed Apr 15, 2026.
Congress
Members of Congress filed 3 disclosures on Genprex in the 12 months to Nov 19, 2026: 3 purchases and 0 sales, by 1 member. In the 12 months before that: 1 disclosure.
The largest range: Rep. Tim Moore (NC14), $1,001 to $15,000, filed Jan 7, 2026.
Contracts, lobbying and filings
ClinicalTrials.gov shows 2 studys sponsored by the company updated in the period; the latest, "Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Os..." (Phase 2, status recruiting), was updated on Sep 16, 2026, with primary completion listed for 2028-03.
FINRA short interest for GNPX on the settlement date of Oct 30, 2026 was 123,259 shares (-1.33% on the previous report), about 1 days of average volume.
For fiscal 2025, the company's proxy statement reported total compensation of $729K for its principal executive officer, and an average of $689K for the other named executive officers.
Company reports, price and press
Genprex filed a Form 8-K on Aug 5, 2026 (Item 3.01) that OQRO classes as: received a notice from its stock exchange.
The company's own opening sentence of that report reads: "On August 4, 2026, the Company was formally notified that the Panel determined that the Company has regained compliance with the Bid Price Requirement."
Genprex filed a Form 8-K on Jul 30, 2026 (Items 3.01, 8.01) that OQRO classes as: received a notice from its stock exchange, and reported other company news.
The company's own opening sentence of that report reads: "On July 29, 2026, the Nasdaq Hearings Panel (the 'Panel') notified Genprex, Inc. (the 'Company' or 'Genprex') that it has granted the Company’s request to continue the Company’s listing on The Nasdaq Capital Market ('Nasdaq') and..."
Genprex filed a Form 8-K on Jun 18, 2026 (Items 5.02, 5.07) that OQRO classes as: changed a top executive or board member, and held a shareholder vote.
The company's own opening sentence of that report reads: "On June 18, 2026 at the 2026 Annual Meeting of Stockholders (the '2026 Annual Meeting') of Genprex, Inc. (the 'Company' or 'Genprex'), the Company’s stockholders approved the Company’s amended and restated 2018 Equity Incentive P..."
Press coverage listed by Finnhub: "Genprex to Highlight Dual Delivery Strategy for Diabetes Gene Therapy at Future of Cell and Gene Therapy Symposium" (Yahoo, Nov 11, 2026).
Press coverage listed by Finnhub: "Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference" (Yahoo, Sep 8, 2026).
Press coverage listed by Finnhub: "Andelyn Biosciences to Scale Manufacturing for Genprex's Diabetes Gene Therapy Program" (Yahoo, Sep 1, 2026).
GNPX closed at $1.71 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $2.06 to $1.71, a change of −17.0%.
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO.
Latest annual report filed Mar 30, 2026, compared with the one filed Apr 1, 2025. Read the filing
No longer listed (1 heading from the year before)
We will likely continue to incur increased costs and devote additional management time to public company reporting and compliance obligations as a result of exiting “emerging growth company” status.
Legal proceedings (Item 3)
From time to time, we may be involved in legal proceedings that arise during the ordinary course of business. Although the results of legal proceedings cannot be predicted with certainty, we do not currently have any pending litigation to which we are a party or to which our property is subject that we believe to be material. Regardless of the outcome, litigation can be costly and time consuming, and it can divert management’s attention from important business matters and initiatives, negatively impacting our overall operations.
Source: SEC EDGAR, Form 10-K filed Mar 30, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 7,000 words.
From “Overview”, in the company's words
We are a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs. Our oncology platform utilizes our systemic, non-viral ONCOPREX® Delivery System which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. The product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. Our diabetes technology is designed to work in Type 1 diabetes by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body’s immune system.
What the section covers (21 headings)
Overview
Oncology Platform
Diabetes Gene Therapy
Convergen Biotech, Inc
Reverse Stock Splits
Recently Issued Accounting Pronouncements
Critical Accounting Policies and Significant Judgments and Estimates
Research and Development Costs
Income Taxes
Impairment of Long-Lived Assets
Modification of Equity Classified Warrants
Components of our Results of Operations and Financial Condition
Operating expenses
Results of Operations
And 7 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 30, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Off-exchange trading: 59.7% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (3.2% on ATS, 56.5% with other brokers), above its 13-week average of 50.9%. Weeks of Sep 21 to Oct 16, 2026.
Week of Jul 20ATSOther off-exchangeFull height = all shares tradedWeek of Oct 12
Largest ATS: UBS ATS (26.1%), INTELLIGENT CROSS LLC (7.5%), VIRTU MATCHIT ATS (5.6%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.